27 articles found
Browse Rainier Rehab's editorial coverage of Mental health. Our writers track federal and state policy, peer-reviewed research, treatment innovations, and frontline reporting from the addiction recovery field. Each article in this collection cites primary sources — government datasets (SAMHSA, NIH, CDC), Medicaid and Medicare bulletins, JAMA and Lancet studies, and on-the-record statements from clinicians, regulators, and people in recovery — so readers can verify claims and dig deeper.
We update this tag whenever new mental health reporting publishes. If you're a researcher, journalist, or family member trying to make sense of substance use disorder treatment, this is the working archive. For a directory of accredited treatment facilities, visit our facilities directory; to compare modalities, see our treatments overview and levels of care guide.
In a national sample of 58,000 adults with opioid, alcohol or cannabis dependence, men had lower odds of depression and anxiety but higher odds of psychosis.
Ohio's sober living homes grew 400% in four years. Now Ohio, Georgia and Arizona are writing new rules on certification, fraud oversight and zoning.
Study of 2,053 treatment facilities finds gabapentin prescribing rising despite weak evidence; unprescribed use runs nearly double the prescription rate.
2025 NSDUH data shows first decline in adolescent suicidal ideation since 2021, but experts urge caution as rates remain historically high.
New research reveals that alcohol abstinence triggers changes in the BNST brain region, potentially increasing compulsive drinking urges before relapse occurs.
New federal funding aims to keep families together by providing peer support services to parents battling addiction, reducing foster care placements.
Oregon State University research reveals higher morning cortisol levels in regular cannabis users, potentially linking to use consequences rather than frequency alone.
SAMHSA announced $73.2 million in grants across three programs: children's mental health services, Zero Suicide implementation, and assisted outpatient treatment.
A new Illinois law folds gambling disorder into the state's Substance Use Disorder Act, unlocking school education, screening, and suicide prevention programs.
Compass Pathways' COMP360 psilocybin therapy achieves primary endpoints in two Phase 3 trials for treatment-resistant depression, with FDA submission planned for late 2026.
Landmark global analysis reveals decriminalization doesn't raise use, but for-profit markets drive higher addiction rates and more potent products.
HHS Secretary Robert F. Kennedy Jr. unveils major funding package emphasizing faith-based recovery programs and evidence-based treatment for vulnerable populations.
University of Southern California receives funding to launch its first clinical study of psilocybin-assisted therapy combined with mindfulness meditation for mental well-being.
New UCLA research finds that California adolescents using drugs or alcohol face triple the suicide risk, with nearly half experiencing serious psychological distress.
The Department of Veterans Affairs begins groundbreaking clinical trial testing MDMA-assisted therapy for veterans struggling with PTSD and alcohol use disorder, marking a significant federal investment in psychedelic medicine.
State insurance regulators find Aetna, Anthem, Cigna, ConnectiCare, and UnitedHealthcare systematically underpaid mental health providers and restricted access to care.
First randomized double-blind study in Sweden finds psilocybin provides clinically meaningful depression relief within days, with 53% remission rate at six weeks.
UC San Francisco and Imperial College London researchers discover that one 25mg dose of psilocybin creates measurable anatomical brain changes lasting at least a month.
Texas is developing a medical psilocybin program to treat depression, PTSD, and substance use disorders, with support from Trump's executive order and FDA fast-tracking.
American Hospital Association urges federal investment in loan repayment and training programs to address severe provider shortages affecting 75% of rural health professional shortage areas.
New research reveals 40% of Americans face mental health provider shortages, with rural and low-income communities hardest hit. States respond with loan repayment programs, pipeline initiatives, and data-driven workforce planning.
Togus VA Medical Center opens Maine's first residential substance use disorder program for veterans, ending years of out-of-state travel for inpatient care.
Study of 600,000 U.S. veterans finds GLP-1 drugs like Ozempic and Wegovy associated with dramatic reductions in substance use disorder complications, overdoses, and deaths.
President Trump signed an executive order accelerating psychedelic drug research, directing FDA priority vouchers, Right to Try access, and $50 million in federal-state partnerships.
New transparency tool reveals patients face 24-83% fewer in-network options for mental health care, while clinicians earn 16-59% less than physical health providers.
New Pew research reveals 40% of Americans face provider shortages, with rural counties three times more likely to lack psychologists. States respond with loan repayment and pipeline programs.
ONDCP, SAMHSA, and HUD launch two-day summit to develop national toolkit for treating substance use disorders among homeless populations.